Physician profile
Kenneth Widder
NPI 1861885295
$1,032,588.93
in general payments reported to CMS, 2019-2025
2 companies · $257K in 2025
The $257K reported for 2025 was more than what 99% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $195K · 2021: $249K · 2022: $1,725 · 2024: $329K · 2025: $257K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $582K · Travel and Lodging: $2,097 · Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $582,443.32 |
| Travel and Lodging | $2,096.92 |
| Food and Beverage | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho-Clinical Diagnostics, INC. | $585,240.24 | 2024-2025 | |
| Quidel Corporation | $447,348.69 | 2019-2022 |
Research and ownership
$1,155,634.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Widder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.